A Complete Response Induced by 21-day Sorafenib Therapy in a Patient with Advanced Hepatocellular Carcinoma
The response rate and overall survival after sorafenib administration in patients with advanced hepatocellular carcinoma are unsatisfactory. We herein present the case of a 65-year-old man with multiple lung metastases of hepatocellular carcinoma. Because the patient had liver cirrhosis of Child-Pug...
Gespeichert in:
| Veröffentlicht in: | Internal Medicine 2013, Vol.52(14), pp.1589-1592 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1592 |
|---|---|
| container_issue | 14 |
| container_start_page | 1589 |
| container_title | Internal Medicine |
| container_volume | 52 |
| creator | Hagihara, Atsushi Teranishi, Yuga Kawamura, Etsushi Fujii, Hideki Iwai, Shuji Morikawa, Hiroyasu Enomoto, Masaru Tamori, Akihiro Kawada, Norifumi |
| description | The response rate and overall survival after sorafenib administration in patients with advanced hepatocellular carcinoma are unsatisfactory. We herein present the case of a 65-year-old man with multiple lung metastases of hepatocellular carcinoma. Because the patient had liver cirrhosis of Child-Pugh B accompanied by pancytopenia, sorafenib administration was initiated at a dose of 400 mg daily. Although he received sorafenib for only 21 days, the patient exhibited complete regression of the tumors. There was no clinical evidence of recurrence without the administration of anticancer treatment. It is unique that short-term sorafenib treatment achieved a complete response. |
| doi_str_mv | 10.2169/internalmedicine.52.9340 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1400622511</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1400622511</sourcerecordid><originalsourceid>FETCH-LOGICAL-c527t-5f334836c5c5dc15ce20170015432a74ed22367d8ecc3c406e2e7c7ff29cfa13</originalsourceid><addsrcrecordid>eNptkE9P3DAQxa0KBFvgKyAfuWTrP3GcHFcrKEhIVO3erVln0jUkTrAd0H77JtrtHqpeZg7ze--NHiGUs6XgRfXN-YTBQ9th7azzuFRiWcmcfSELLvMq00KqM7JgFS8zMY1L8jXGV8ZkqStxQS6FLJWergvytqLrvhtaTEh_Yhx6H5E--Xq0WNPtngqe1bCnv_oADXq3pZsdBhj21HkK9Ackhz7RT5d2dFV_gJ9ljzhA6i227dhCoGsI0499B9fkvIE24s1xX5HNw_1m_Zg9v3x_Wq-eM6uETplqpMxLWVhlVW25sigY14xxlUsBOsdaCFnoukRrpc1ZgQK11U0jKtsAl1fk7mA7hP59xJhM5-L8DXjsx2h4zlghhOIzWh5QG_oYAzZmCK6DsDecmblp82_TRgkzNz1Jb48p43Y6noR_q52AlwPwGhP8xhMAITnb4n-deT7PY8SJtDsIBr38AxMenH8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1400622511</pqid></control><display><type>article</type><title>A Complete Response Induced by 21-day Sorafenib Therapy in a Patient with Advanced Hepatocellular Carcinoma</title><source>J-STAGE Free</source><source>MEDLINE</source><creator>Hagihara, Atsushi ; Teranishi, Yuga ; Kawamura, Etsushi ; Fujii, Hideki ; Iwai, Shuji ; Morikawa, Hiroyasu ; Enomoto, Masaru ; Tamori, Akihiro ; Kawada, Norifumi</creator><creatorcontrib>Hagihara, Atsushi ; Teranishi, Yuga ; Kawamura, Etsushi ; Fujii, Hideki ; Iwai, Shuji ; Morikawa, Hiroyasu ; Enomoto, Masaru ; Tamori, Akihiro ; Kawada, Norifumi</creatorcontrib><description>The response rate and overall survival after sorafenib administration in patients with advanced hepatocellular carcinoma are unsatisfactory. We herein present the case of a 65-year-old man with multiple lung metastases of hepatocellular carcinoma. Because the patient had liver cirrhosis of Child-Pugh B accompanied by pancytopenia, sorafenib administration was initiated at a dose of 400 mg daily. Although he received sorafenib for only 21 days, the patient exhibited complete regression of the tumors. There was no clinical evidence of recurrence without the administration of anticancer treatment. It is unique that short-term sorafenib treatment achieved a complete response.</description><identifier>ISSN: 0918-2918</identifier><identifier>EISSN: 1349-7235</identifier><identifier>DOI: 10.2169/internalmedicine.52.9340</identifier><identifier>PMID: 23857091</identifier><language>eng</language><publisher>Japan: The Japanese Society of Internal Medicine</publisher><subject>Aged ; Antineoplastic Agents - administration & dosage ; Carcinoma, Hepatocellular - drug therapy ; Carcinoma, Hepatocellular - pathology ; complete response ; Drug Administration Schedule ; hepatocellular carcinoma ; Humans ; Liver Neoplasms - drug therapy ; Liver Neoplasms - pathology ; Male ; Niacinamide - administration & dosage ; Niacinamide - analogs & derivatives ; Phenylurea Compounds - administration & dosage ; Remission Induction - methods ; Sorafenib ; Treatment Outcome</subject><ispartof>Internal Medicine, 2013, Vol.52(14), pp.1589-1592</ispartof><rights>2013 by The Japanese Society of Internal Medicine</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c527t-5f334836c5c5dc15ce20170015432a74ed22367d8ecc3c406e2e7c7ff29cfa13</citedby><cites>FETCH-LOGICAL-c527t-5f334836c5c5dc15ce20170015432a74ed22367d8ecc3c406e2e7c7ff29cfa13</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,1883,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23857091$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hagihara, Atsushi</creatorcontrib><creatorcontrib>Teranishi, Yuga</creatorcontrib><creatorcontrib>Kawamura, Etsushi</creatorcontrib><creatorcontrib>Fujii, Hideki</creatorcontrib><creatorcontrib>Iwai, Shuji</creatorcontrib><creatorcontrib>Morikawa, Hiroyasu</creatorcontrib><creatorcontrib>Enomoto, Masaru</creatorcontrib><creatorcontrib>Tamori, Akihiro</creatorcontrib><creatorcontrib>Kawada, Norifumi</creatorcontrib><title>A Complete Response Induced by 21-day Sorafenib Therapy in a Patient with Advanced Hepatocellular Carcinoma</title><title>Internal Medicine</title><addtitle>Intern. Med.</addtitle><description>The response rate and overall survival after sorafenib administration in patients with advanced hepatocellular carcinoma are unsatisfactory. We herein present the case of a 65-year-old man with multiple lung metastases of hepatocellular carcinoma. Because the patient had liver cirrhosis of Child-Pugh B accompanied by pancytopenia, sorafenib administration was initiated at a dose of 400 mg daily. Although he received sorafenib for only 21 days, the patient exhibited complete regression of the tumors. There was no clinical evidence of recurrence without the administration of anticancer treatment. It is unique that short-term sorafenib treatment achieved a complete response.</description><subject>Aged</subject><subject>Antineoplastic Agents - administration & dosage</subject><subject>Carcinoma, Hepatocellular - drug therapy</subject><subject>Carcinoma, Hepatocellular - pathology</subject><subject>complete response</subject><subject>Drug Administration Schedule</subject><subject>hepatocellular carcinoma</subject><subject>Humans</subject><subject>Liver Neoplasms - drug therapy</subject><subject>Liver Neoplasms - pathology</subject><subject>Male</subject><subject>Niacinamide - administration & dosage</subject><subject>Niacinamide - analogs & derivatives</subject><subject>Phenylurea Compounds - administration & dosage</subject><subject>Remission Induction - methods</subject><subject>Sorafenib</subject><subject>Treatment Outcome</subject><issn>0918-2918</issn><issn>1349-7235</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNptkE9P3DAQxa0KBFvgKyAfuWTrP3GcHFcrKEhIVO3erVln0jUkTrAd0H77JtrtHqpeZg7ze--NHiGUs6XgRfXN-YTBQ9th7azzuFRiWcmcfSELLvMq00KqM7JgFS8zMY1L8jXGV8ZkqStxQS6FLJWergvytqLrvhtaTEh_Yhx6H5E--Xq0WNPtngqe1bCnv_oADXq3pZsdBhj21HkK9Ackhz7RT5d2dFV_gJ9ljzhA6i227dhCoGsI0499B9fkvIE24s1xX5HNw_1m_Zg9v3x_Wq-eM6uETplqpMxLWVhlVW25sigY14xxlUsBOsdaCFnoukRrpc1ZgQK11U0jKtsAl1fk7mA7hP59xJhM5-L8DXjsx2h4zlghhOIzWh5QG_oYAzZmCK6DsDecmblp82_TRgkzNz1Jb48p43Y6noR_q52AlwPwGhP8xhMAITnb4n-deT7PY8SJtDsIBr38AxMenH8</recordid><startdate>20130101</startdate><enddate>20130101</enddate><creator>Hagihara, Atsushi</creator><creator>Teranishi, Yuga</creator><creator>Kawamura, Etsushi</creator><creator>Fujii, Hideki</creator><creator>Iwai, Shuji</creator><creator>Morikawa, Hiroyasu</creator><creator>Enomoto, Masaru</creator><creator>Tamori, Akihiro</creator><creator>Kawada, Norifumi</creator><general>The Japanese Society of Internal Medicine</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20130101</creationdate><title>A Complete Response Induced by 21-day Sorafenib Therapy in a Patient with Advanced Hepatocellular Carcinoma</title><author>Hagihara, Atsushi ; Teranishi, Yuga ; Kawamura, Etsushi ; Fujii, Hideki ; Iwai, Shuji ; Morikawa, Hiroyasu ; Enomoto, Masaru ; Tamori, Akihiro ; Kawada, Norifumi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c527t-5f334836c5c5dc15ce20170015432a74ed22367d8ecc3c406e2e7c7ff29cfa13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Aged</topic><topic>Antineoplastic Agents - administration & dosage</topic><topic>Carcinoma, Hepatocellular - drug therapy</topic><topic>Carcinoma, Hepatocellular - pathology</topic><topic>complete response</topic><topic>Drug Administration Schedule</topic><topic>hepatocellular carcinoma</topic><topic>Humans</topic><topic>Liver Neoplasms - drug therapy</topic><topic>Liver Neoplasms - pathology</topic><topic>Male</topic><topic>Niacinamide - administration & dosage</topic><topic>Niacinamide - analogs & derivatives</topic><topic>Phenylurea Compounds - administration & dosage</topic><topic>Remission Induction - methods</topic><topic>Sorafenib</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hagihara, Atsushi</creatorcontrib><creatorcontrib>Teranishi, Yuga</creatorcontrib><creatorcontrib>Kawamura, Etsushi</creatorcontrib><creatorcontrib>Fujii, Hideki</creatorcontrib><creatorcontrib>Iwai, Shuji</creatorcontrib><creatorcontrib>Morikawa, Hiroyasu</creatorcontrib><creatorcontrib>Enomoto, Masaru</creatorcontrib><creatorcontrib>Tamori, Akihiro</creatorcontrib><creatorcontrib>Kawada, Norifumi</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Internal Medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hagihara, Atsushi</au><au>Teranishi, Yuga</au><au>Kawamura, Etsushi</au><au>Fujii, Hideki</au><au>Iwai, Shuji</au><au>Morikawa, Hiroyasu</au><au>Enomoto, Masaru</au><au>Tamori, Akihiro</au><au>Kawada, Norifumi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A Complete Response Induced by 21-day Sorafenib Therapy in a Patient with Advanced Hepatocellular Carcinoma</atitle><jtitle>Internal Medicine</jtitle><addtitle>Intern. Med.</addtitle><date>2013-01-01</date><risdate>2013</risdate><volume>52</volume><issue>14</issue><spage>1589</spage><epage>1592</epage><pages>1589-1592</pages><issn>0918-2918</issn><eissn>1349-7235</eissn><abstract>The response rate and overall survival after sorafenib administration in patients with advanced hepatocellular carcinoma are unsatisfactory. We herein present the case of a 65-year-old man with multiple lung metastases of hepatocellular carcinoma. Because the patient had liver cirrhosis of Child-Pugh B accompanied by pancytopenia, sorafenib administration was initiated at a dose of 400 mg daily. Although he received sorafenib for only 21 days, the patient exhibited complete regression of the tumors. There was no clinical evidence of recurrence without the administration of anticancer treatment. It is unique that short-term sorafenib treatment achieved a complete response.</abstract><cop>Japan</cop><pub>The Japanese Society of Internal Medicine</pub><pmid>23857091</pmid><doi>10.2169/internalmedicine.52.9340</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0918-2918 |
| ispartof | Internal Medicine, 2013, Vol.52(14), pp.1589-1592 |
| issn | 0918-2918 1349-7235 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1400622511 |
| source | J-STAGE Free; MEDLINE |
| subjects | Aged Antineoplastic Agents - administration & dosage Carcinoma, Hepatocellular - drug therapy Carcinoma, Hepatocellular - pathology complete response Drug Administration Schedule hepatocellular carcinoma Humans Liver Neoplasms - drug therapy Liver Neoplasms - pathology Male Niacinamide - administration & dosage Niacinamide - analogs & derivatives Phenylurea Compounds - administration & dosage Remission Induction - methods Sorafenib Treatment Outcome |
| title | A Complete Response Induced by 21-day Sorafenib Therapy in a Patient with Advanced Hepatocellular Carcinoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T13%3A49%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20Complete%20Response%20Induced%20by%2021-day%20Sorafenib%20Therapy%20in%20a%20Patient%20with%20Advanced%20Hepatocellular%20Carcinoma&rft.jtitle=Internal%20Medicine&rft.au=Hagihara,%20Atsushi&rft.date=2013-01-01&rft.volume=52&rft.issue=14&rft.spage=1589&rft.epage=1592&rft.pages=1589-1592&rft.issn=0918-2918&rft.eissn=1349-7235&rft_id=info:doi/10.2169/internalmedicine.52.9340&rft_dat=%3Cproquest_cross%3E1400622511%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1400622511&rft_id=info:pmid/23857091&rfr_iscdi=true |